Benzinga | Jan 7, 2022 01:01PM EST

Stephens & Co. Initiates Coverage On Castle Biosciences with Overweight Rating, Announces Price Target of $59

Stephens & Co. initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Overweight rating and announces Price Target of $59.